dc.contributor
Institut Català de la Salut
dc.contributor
[de Jager VD] Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. [Giacomini P] UOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Member of the European Liquid Biopsy Society (ELBS) ctDNA Working Group, Hamburg, Germany. [Fairley JA] GenQA, Department of Laboratory Medicine, NHS Lothian, Nine, Edinburgh Bioquarter, Edinburgh, United Kingdom. [Toledo RA] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Patton SJ] EMQN CIC, Unit 4, Enterprise House, Manchester Science Park, Pencroft Way, Manchester, United Kingdom. [Joosse SA] Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
de Jager, Vincent D.
dc.contributor.author
Giacomini, Patrizio
dc.contributor.author
Fairley, Jennifer A.
dc.contributor.author
Patton, Simon
dc.contributor.author
Joosse, Simon A.
dc.contributor.author
Toledo, Rodrigo
dc.date.accessioned
2025-10-25T05:37:39Z
dc.date.available
2025-10-25T05:37:39Z
dc.date.issued
2025-04-29T12:20:34Z
dc.date.issued
2025-04-29T12:20:34Z
dc.identifier
de Jager VD, Giacomini P, Fairley JA, Toledo RA, Patton SJ, Joosse SA, et al. Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop. eBioMedicine. 2025 Apr;114:105636.
dc.identifier
http://hdl.handle.net/11351/13012
dc.identifier
10.1016/j.ebiom.2025.105636
dc.identifier
001326612900112
dc.identifier.uri
http://hdl.handle.net/11351/13012
dc.description.abstract
Consensus; Liquid biopsy; ctDNA test
dc.description.abstract
Consenso; Biopsia líquida; Prueba de ADNct
dc.description.abstract
Consens; Biòpsia líquida; Prova d'ADNct
dc.description.abstract
The implementation of circulating tumor DNA (ctDNA) in the diagnostic routine may enable non-invasive predictive biomarker testing and treatment optimization in patients who lack a suitable tumor specimen, have failed previous molecular analysis or are clinically ineligible for (re-)biopsy procedures. As the interpretation and reporting are more complex for ctDNA than conventional tissue-based NGS, there is a need for specific guidelines. These will offer support for the reporting of ctDNA test results and will facilitate optimal communication of liquid biopsy findings between diagnostic laboratories and the medical oncology team. Aiming to generate guidelines based on real-world experiences and broad perspectives, we organized a European Liquid Biopsy Society (ELBS) ctDNA workshop, in which forty-four experts and key stakeholders from different molecular diagnostics laboratories, oncology and pathology departments, as well as an IVDR specialist, convened to address significant challenges associated with the reporting of liquid biopsy test results. This report delineates the resulting consensus recommendations for ctDNA test reporting with underlying rationale and background information.
dc.description.abstract
This study was funded by the EU project CAN.HEAL, grant n. 101080009 (KP, SAJ, PG). The views and opinions expressed are those of the authors only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them.
dc.format
application/pdf
dc.relation
eBioMedicine;114
dc.relation
https://doi.org/10.1016/j.ebiom.2025.105636
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Diagnòstic
dc.subject
Càncer - Aspectes genètics
dc.subject
Decisió, Presa de
dc.subject
CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Cell-Free Nucleic Acids::Circulating Tumor DNA
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Liquid Biopsy
dc.subject
DISEASES::Neoplasms
dc.subject
Other subheadings::Other subheadings::/diagnosis
dc.subject
PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::ácidos nucleicos::ácidos nucleicos libres de células::ADN tumoral circulante
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::biopsia líquida
dc.subject
ENFERMEDADES::neoplasias
dc.subject
Otros calificadores::Otros calificadores::/diagnóstico
dc.subject
PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso
dc.title
Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
